Boehringer Ingelheim Articles
MediChem gets commercialization rights to anti-HIV calanolides
11 September 1995
Reversal Of Bronchodilator Domination By 2000
4 September 1995
GATT Changes Effect 42% Of US Drug Patents
21 August 1995
Chiroscience appointment
14 August 1995
Orphan Status For Mitolactol
24 July 1995
Boehringer Ingelheim In Deal With Isis
24 July 1995
Real Threat To Glaxo's Zantac Patent Is Possible
24 July 1995
Boeh Ing launches Combivent UDV
3 July 1995
World Pharma Firm League, According To PMSI
3 July 1995
Boeh Ingelheim Investing In Brazil
26 June 1995
Boeh Ingelheim/Sequana Asthma Genetics Alliance
26 June 1995
Glaxo Wellcome Patent Battles Continue
19 June 1995
Boehringer Ingelheim Tightens Up In Spain
19 June 1995
Boehringer Ingelheim In Talks With US Co
5 June 1995
The ABPI's A-Z Of British Medicines Research
29 May 1995
Biotech Financing By Pharma Industry
22 May 1995
US Biotech Deal-Making Led By R&D Efficiency
24 April 1995
Boeh Ingelheim's Antiherpetic Drug
20 March 1995
UK Code Authority May Become Self-Supporting
20 March 1995
Expanded Access Urged For Protease Inhibitors
13 March 1995
Merger Forms Cancer And Anti-Infectives Specialist
6 March 1995
Boehringer Ingelheim Expands In Mexico
13 February 1995
Betaseron Is Schering's Most Successful Drug Ever
13 February 1995
Nippon Boehringer Ingelheim Appointment
6 February 1995
Nippon Boehringer Ingelheim Marketing News
6 February 1995
New Chemical Entities Round-Up For 1994
6 February 1995
Boeh Ingelheim To Develop Cerestat
16 January 1995
Astra Again Leading Performer, Says Insight
19 December 1994
New S African Distribution Venture Claims Success
7 November 1994
HIV Therapy Options Examined
31 October 1994
Glaxo Leads Pharma World League, Says DDT
17 October 1994
ACE Inhibitor Launched In Japan
26 September 1994
Employment Implications Of Mergers, Restructuring
5 September 1994
MATRITECH/BI DEAL
15 August 1994
Tokyo Stock Comment
25 July 1994
B-I Receives Two Approval Recommendations In USA
25 July 1994
Boehringer Ingelheim Assigns Quest Account
18 July 1994
EUROPEAN CORPORATE NEWS IN BRIEF
4 July 1994
BIOPHARMA GROWTH MARKETS OF THE FUTURE
27 June 1994
BOEH INGELHEIM LAUNCHES ANDANTE
30 May 1994
BOEHRINGER INGELHEIM REDEFINES STRATEGIES
30 May 1994
FIRMS TO SHARE AIDS DRUG TRIAL DATA
25 April 1994
JAPANESE COs TOO DEPENDENT ON HOME MKT
11 April 1994
JAPANESE DRUG APPROVALS
21 March 1994
BOEHRINGER INGELHEIM RECEIVES NOT APPROVABLE LETTER
14 March 1994
BOEH INGELHEIM RECALLS ALUPENT
14 February 1994
HARNAL LICENSE AGREEMENT
31 January 1994
SANKYO, NBI IN CROSS LICENSING DEAL
31 January 1994
WORLD PRODUCT NEWS IN BRIEF
24 January 1994
CONFLICT OVER BOEH-INGELHEIM PLAN
10 January 1994
NEW NHI LIST ADDITIONS IN JAPAN
20 December 1993
AUSTRALIA (KINGAROY) PHARMA BOOM FORECAST
6 December 1993
JAPANESE FIRST-HALF RESULTS AND FORECASTS
6 December 1993
SCHERING SAYS DRUG BUSINESS WILL GROW
22 November 1993
ATROVENT APPROVAL
25 October 1993
DRUG COs ADAPTING TO A CHANGING INDUSTRY
25 October 1993
MERCK DISCONTINUES L661 DEVELOPMENT
20 September 1993
BOEHRINGER LAUNCHES MOTENS
9 August 1993
APPOINTMENT AT BOEHRINGER INGELHEIM RESEARCH
19 July 1993
BOEHRINGER INGELHEIM GETS GO-AHEAD FOR US TRIALS
19 July 1993
PROFITS SOAR FOR GENENTECH IN 2ND QTR
19 July 1993
COMPETITIVE DYNAMICS IN PHARMA INDUSTRY
28 June 1993
NNRT INHIBITORS IN CLINICAL DEVELOPMENT
21 June 1993
THOMAE SALES UP
21 June 1993
BOEHRINGER APPOINTMENTS
26 April 1993
DRUG FIRMS TO WORK TOGETHER ON AIDS R&D
26 April 1993
PROFIT FALL IN JAPAN FOR BOEH-INGELHEIM
26 April 1993
UPJOHN ANTI-HIV AGENTS IN PHASE II TRIALS
5 April 1993
WAYWARD ADVERTISING OF PRODUCTS IN FRANCE
5 April 1993
POSITIVE EVENTS FOR IDEC PHARMA
29 March 1993
PHARMACEUTICAL DESIGN: EPITOPE SELECTION
15 March 1993
JANSSEN TO PRESS ON WITH R 89439 DEV'T
8 March 1993
TRIPLE THERAPY FOR HIV INFECTION
1 March 1993
WORLD RESPIRATORY PRODUCTS MARKET
1 March 1993
NEVIRAPINE IN AIDS PATIENTS
22 February 1993
NEW DIRECTORS AT CIBUS
25 January 1993
MARINOL APPROVED FOR AIDS ANOREXIA
18 January 1993
LOSEC SALES TO TOP $1 BILLION IN 1992
21 December 1992
NEW ATHEROSCLEROSIS GUIDELINES FOR EUROPE
14 December 1992
FRENCH GOVT HOLDS ON R-P SHARE SALE
14 December 1992
BOEH-INGELHEIM'S IMMUKIN LAUNCHED IN UK
7 December 1992
NEW PRESIDENT AT BOEHRINGER
9 November 1992
NEW DRUGS HIGHLIGHTED AT AIDS CONFERENCE
3 August 1992
IDEC RATING RAISED ON TRIAL GO-AHEAD
29 June 1992
IDEC'S SPECIFID TRIAL GETS GO-AHEAD
22 June 1992
THOMAE SALES RISE BY PROFITS DOWN
22 June 1992
Boeh-Ingelheim Closes European Plants
8 June 1992
BOEH INGELHEIM LINKS WITH NEORX
8 June 1992
SPARFLOXACIN DEAL
25 May 1992
CHOLESTECH'S HARVEY SADOW
4 May 1992
PROJECT REVIEW FROM NOVO NORDISK
27 April 1992
BOEH INGELHEIM CHF DRUG DISCONTINUED
23 March 1992
OTC HYOSCINE BUTYLBROMIDE LAUNCHED IN UK
9 March 1992
PRODUCT APPROVALS FOR GLAXO
27 January 1992
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
